Circassia Plans $285 Million IPO to Fund Allergy Vaccines

Circassia Holdings Ltd., a U.K. biotechnology company developing allergy vaccines, plans to raise about 175 million pounds ($285 million) in an initial public offering on the London Stock Exchange.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.